Nanocan Therapeutics Corporation
↗Princeton, New Jersey (also noted as National Harbor, MD)
Nanocan Therapeutics Corporation is an early-stage biotechnology company developing novel drug-delivery nanotechnology for more precise and targeted treatment of cancer and respiratory diseases. The company's proprietary technology platform deploys smart radiotherapy biomaterials (nanoparticle drones) as a drug-delivery system capable of sustainably delivering multiple drug payloads—including immunotherapy drugs, chemotherapy drugs, and phytomedicines—precisely to disease sites. Nanocan owns the exclusive global license to patented Immunogenic Smart Radiotherapy Biomaterial (iSRB) technology invented at Brigham and Women's Hospital, a teaching hospital of Harvard University's medical school. The company is committed to making combination radiotherapy and immunotherapy available to cancer patients, with particular focus on treating pancreatic cancer, prostate cancer, glioblastoma, and cervical cancer, with partnerships extending into Low and Middle-Income Countries (LMICs) in Africa.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Seed/Early Stage
Total Raised:$6.4M
Investors:AIN Ventures, Alliance of Angels, Prevail Partners, Sand Hill Angels, National Institutes of Health (NIH), Lifeforce Capital GP I, Bearcat Investments
PIPELINE
Stage:Phase I/II
Lead Drug Stage:Phase I/II (Onychomycosis indication)
Modalities:Nanoparticle Drug Delivery, Smart Radiotherapy Biomaterials, Combination Radiotherapy, Immunotherapy, Chemotherapy
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Brigham and Women's Hospital (Boston, MA) - Exclusive global license for iSRB technology development and commercialization for pancreatic, lung, and cervical cancer, Harvard University Medical School - Academic research partnership, Dana-Farber Cancer Institute - Partnership for cancer research, Leading cancer treatment centers in Africa, Partners in Nigeria, Kenya, and South Africa, US and UK universities - International collaboration network
COMPETITION
Position:Emerging
Competitors:D2M Biotherapeutics, Cadent Therapeutics, Modis Therapeutics, Immunophotonics, Advanced Chemotherapy Technologies, Oncotex
LEADERSHIP
Key Executives:
Eric Broyles - Founder & Chief Executive Officer
Jacques P. Walker - Co-Founder
Board Members:Dr. Paul Wallner (Advisory Board Member), Dr. Elder Granger (Advisory Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nanocan Therapeutics Corporation. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.